Reports Q4 Adjusted EBITDA C$16.7M vs. C$2.3M last year. “We are pleased to report an exceptional year to our shareholders, highlighted by record annual global medical net revenue, adjusted EBITDA, and positive free cash flow. These achievements underscore the thoughtful execution of our strategic plan, set us further apart from competitors, and strengthen our foundation for sustained and profitable growth,” said Executive Chairman and CEO for Aurora, Miguel Martin.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Is Aurora Cannabis (ACB) a Good Stock to Buy before Earnings?
- Options Volatility and Implied Earnings Moves This Week, June 16 – June 20, 2025
- ACB Upcoming Earnings Report: What to Expect?
- Aurora Cannabis launches IndiMed TEMPO 22 cannabis offering in Australia
- Aurora Cannabis to Discuss Fiscal Year 2025 Results in Upcoming Investor Call